Selective growth story; revenue upsell masks margin compression
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Reaffirmed manufacturing margin guidance (INR5-7/L); acknowledged glass inflation and raw-material headwinds; P&A investment thesis (losses today for scale) credible. But omitted 32% of consolidated revenue from narrative.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Management executed volume growth (P&A +45%, UP R&O 2.4x) and reaffirmed manufacturing margins (INR5-7/L), but consolidated revenue of ₹1,152 Cr fell short of segment-level disclosure of ₹789 Cr (₹363 Cr unattributed to core narrative). Net profit margin compressed to 2.3% from management's stated 4%, indicating the 'missing' ₹363 Cr (likely ENA/bulk sales) carries sub-1% margins. Strategy is sound but execution narrative was selective.
₹789 Cr
Revenue · +13% YoY₹28 Cr
Reported PAT · +49% YoYCompressing
Margins · vs guidance: OverstatedDid the claims hold up?
Revenue grew 13% YoY to INR789 Cr
OVERSTATEDDelivered result: INR1,151.9 Cr (21.1% YoY). Management reported only ~68% of consolidated revenue
PAT grew 50% YoY to INR28 Cr with 4% margin
OVERSTATEDDelivered PAT INR26.5 Cr (49.7% growth). Margin compressed to 2.3% consolidated vs 4% on reported revenue
Manufacturing EBITDA margin INR6.5/litre (Q1), guidance INR5-7/litre full year
METAt 89% utilization with strong capacity leverage; guidance reaffirmed but contingent on commodity hedging strategy
P&A volumes grew 45% YoY and 45% QoQ to 0.42M cases; revenue grew 35% YoY and 38% QoQ
METNumbers cited; segment still at -INR13 Cr EBITDA as management invests for scale. Acceptable per guidance
R&O volumes grew 13% YoY to 4.48M cases; UP volumes grew 2.4x YoY to 0.2M/month run-rate
METArticulated but no independent verification; UP scale narrative credible given market size (95 lakh cases/month)
Earnings quality
What changed since the last call
Manufacturing margin guidance
NeutralReaffirmed INR5-7/L; Q1 delivered INR6.5/L. No change vs prior guidance, but 89% utilization (vs 85% guidance) signals tighter headroom.
P&A expansion strategy
UpgradeGeographic footprint expanded to 11 states (up from 7 last reported); 4 core states (Delhi, UP, Rajasthan, and 1 unnamed), 6 moving-to-core, 1 early-luxury. FY29 target 500 Cr P&A revenue (vs prior FY29 vision statement vague).
UP R&O scaling
UpgradeCrossed 0.2M cases/month (vs ~0 baseline 12 months ago). 2.4x volume growth YoY is material; mgmt called it 'next big bankable opportunity'.
R&O margin guidance
DowngradeMargins expected to normalize from 17-18% (Rajasthan-heavy) to 15-17% due to UP mix (lower-margin market structure). Mix-driven, not inflation-driven.
The Q&A
Analysts pressed hard on glass/PET inflation (double-digit cost increases cited), glass inflation impact on margins, and Bihar timeline. Management acknowledged glass cost-push but deferred specifics; on Bihar, gave soft 1-2yr estimate without commitments. Q&A did not probe the 363 Cr revenue gap. Moderate pressure, management held firm on guidance.
Ethanol demand drivers — Abneesh Roy, Nuvama
AnsweredE20 core demand ~7-7.5% (aligned with petrol growth); no material impact from controversy. Ethanol offtake 'sticky'. Facility flexibility (ENA/ethanol mix + international sales) allows 89% utilization despite oversupply.
UP R&O growth quantification — Hardik Jatheliya, ARDEKO PMS
PartialDifficult to quantify per-quarter; UP market 95 lakh cases/month, we're aggressive. FY29 guidance given, not quarterly splits. Team executing at fastest pace.
P&A mature vs emerging state split — Hardik Jatheliya, ARDEKO PMS
DodgedStates flow between emerging and core dynamically; benchmarks shift. Core states cross profitability threshold year-3 post-launch. Now 5 core, 6th knocking, target 10 core eventually.
Glass cost inflation mitigation — Abneesh Roy, Nuvama
PartialR&O/P&A cost-pass strategy not detailed; general statement: aggressive growth helps absorb. Energy prices embedded across business.
R&O margin trajectory with UP mix — Himanshu Shah, Dolat Capital
AnsweredMargins will normalize to 15-16% from 17-18% due to UP mix; guidance stands. Doesn't structurally impact business.
IMFL brand portfolio stability — Himanshu Shah, Dolat Capital
AnsweredDifferent states prefer different categories (vodka, semi-premium, deluxe). Geographic expansion drives this naturally. No brand in distress; growth is broad-based.
UK FTA scotch tariff benefit — Nitin Awasthi, InCred
PartialExpect tailwind as inventory transitions, but timing vague. Base price changes by suppliers yet to be seen. FX headwind (Rupee -20% vs Pound YoY) offsets most gains.
West Bengal R&O regulatory clearance — Nitin Awasthi, InCred
AnsweredOn final regulatory hurdle; reasonable view clearance this quarter. Within 60 days of approval, back in market. Market environment neutral to positive.
Manufacturing capacity and capex — Parth Soda, Trinetra Asset Managers
AnsweredNo capacity expansion capex planned through FY29. Only ~50-60 Cr/year maintenance capex. 1% incremental capacity possible from tech improvements.
Raw material inflation hedge — Sucrit Patil, Eyesight Fintrade
AnsweredMulti-legged: FCI fixed-price supply (portion), maize futures hedge, ENA flex-pricing. Broken rice unhedged but seasonal. Confident on INR5-7/L guidance.
Guidance
No FY27 consolidated revenue guidance disclosed
LowManagement focused on segment narratives (13% growth in core business) without consolidated target. Implies flexibility or lack of comfort with full-year outlook.
Manufacturing EBITDA margin INR 5-7/litre for FY27 (reaffirmed)
HighAchieved INR6.5/L in Q1 at 89% utilization. Multi-legged hedge strategy (FCI fixed supply, maize futures, ENA flex-pricing) provides confidence.
R&O EBITDA margin 15-17% for FY27 (normalizing from 17-18%)
HighMix-driven normalization (UP entry with lower-margin structure). Rajasthan stable; UP will drag composite margin slightly but market opportunity large.
Maintenance capex ~INR 50-60 Cr/year; no major capacity expansion through FY29
HighUP facility commissioned; no new plants planned. Incremental capacity via tech improvements (1% upside). All cash generated available for P&A growth or debt pay-down.
Risks the call surfaced
Margin compression
MediumGlass/PET costs up 10-17%; raw material inflation in Q2/Q3 seasonal; consolidated NPM already compressed to 2.3% (vs 4% on core business). Pass-through ability unproven at scale.
Revenue disclosure gap
High363 Cr (32%) of consolidated revenue not attributed to discussed segments; implied sub-1% margin. Raises questions on data quality, segment definition, or undisclosed low-margin businesses.
P&A unit economics unproven
MediumP&A EBITDA negative INR13 Cr despite 35% revenue growth; breakeven timeline not disclosed. If premium brand scaling doesn't achieve 15%+ margins within 2-3 yrs, capex/investment thesis collapses.
UP scaling execution
MediumUP R&O claimed 2.4x volume growth to 0.2M cases/month in massive market (95 lakh/month). Mgmt refused to quantify forward growth ('very difficult'). Risk: growth rate normalizes faster than expected if market saturation or competitive response hits.
FX headwind on scotch/imports
LowUK FTA expected to lower Scotch tariffs, but Rupee depreciation (20% vs Pound YoY) offsets gains. Mgmt said net impact 'not very significant'. Inventory transition timelines vague.
Management
Score 6/10. Moderately clear but selective. Detailed segment narratives for core business (789 Cr) but omitted 363 Cr consolidated gap. Q&A evasions on quantified forward growth and brand-wise performance in P&A. Track record mixed. Reaffirmed manufacturing margin guidance (INR5-7/L); delivered INR6.5/L. UP R&O and P&A scaling on plan. But consolidated revenue disclosure gap raises data quality questions.
1 · Q2-Q3 FY27
UP R&O ramp and gross margin expansion post-harvest (agri commodities deflate Q3-Q4)
2 · Q4 FY27
West Bengal R&O re-entry post regulatory approvals (within 60 days of approval, mgmt said)
3 · Q1-Q2 FY27
UK FTA scotch price benefit materialization (inventory transition dependent, timeline vague)
Strategy is sound but execution narrative was selective.
Volume Growth Can't Hide the Margin Squeeze—or the ₹363 Crore Gap
Revenue jumped 21.1% to ₹1,152 Cr, but management's narrative focused on just ₹789 Cr of growth (13% YoY). The missing ₹363 Cr—one-third of the quarter—is undisclosed low-margin business, and it's pulling consolidated net profit margin down to 2.3%.
On the top line, this looks like a blowout: revenue up 21.1%, PAT up 49.7%. Management walks off the call having reaffirmed its full-year manufacturing margin guidance (₹5–7 per litre) and talked up the P&A footprint (now 11 states) and the UP R&O runaway (2.4x YoY growth). But there's a chasm between what management narrated and what the consolidated result shows. The company detailed ₹789 Cr in revenue across its three core segments—Manufacturing, Regular & Others (R&O), and Prestige & Above (P&A)—representing 13% YoY growth. The actual delivered revenue is ₹1,152 Cr, up 21.1%. The gap: ₹363 Cr—one-third of the quarter—remains unattributed and unanalysed.
₹789 Cr
+13% YoY (mgmt narrative)
₹1,152 Cr
+21.1% YoY (result)
₹363 Cr
32% of total; sub-1% implied margin
That ₹363 Cr gap—almost certainly low-margin ENA (ethanol) bulk sales or commodity trading—is silently dragging consolidated profit margins down. Management reported PAT of ₹26.5 Cr (up 49.7% YoY), but at a net profit margin of just 2.3%. On the core business, at ₹789 Cr in revenue and an implied ₹28 Cr PAT, the margin was closer to 4%. The difference—1.1 percentage points—is the weight of that missing ₹363 Cr.
What management claimed vs. what held up
Revenue grew 13% YoY to ₹789 Cr
Delivered ₹1,152 Cr (21.1% YoY). Management disclosed only ~68% of consolidated revenue.
Overstated
PAT grew 50% YoY to ₹28 Cr with 4% margin
Delivered ₹26.5 Cr (49.7% growth, supported). Consolidated margin 2.3% vs. claimed 4%.
Margin overstated
Manufacturing EBITDA ₹6.5/litre (Q1); guidance ₹5–7/litre FY27
At 89% utilization. Multi-legged hedging (FCI supply, maize futures, ENA flex-pricing) supporting guidance.
Supported
P&A volumes +45% YoY and QoQ to 0.42M cases; revenue +35% YoY, 38% QoQ
Numbers cited. EBITDA −₹13 Cr reflects investment phase, not operational weakness.
Supported
R&O volumes +13% YoY to 4.48M cases; UP volumes 2.4x YoY to 0.2M/month
Narrative credible given UP market size (95 lakh cases/month). No Q&A challenges to the claims.
Supported
What changed on this call
P&A geographic expansion: now in 11 states (4 core, 6 moving-to-core, 1 luxury-early). Up from 7 prior call disclosures.
UP R&O milestone: 0.2M cases/month run-rate (2.4x YoY from near-zero base). Largest growth driver on the call.
R&O margin guidance adjusted: normalizing 15–17% vs prior 17–18%, due to UP mix (lower-margin market structure). Mix-driven, not inflation.
Manufacturing guidance reaffirmed: ₹5–7 per litre for FY27. Q1 delivered ₹6.5/L within band, at 89% utilization.
Capital discipline validated: P&A and UP scaling self-funded from manufacturing/R&O cash. No major capex post-UP commissioning.
The bull-bear ledger
Bull: Volume growth across all segments (P&A +45%, UP R&O 2.4x, manufacturing 89% utilization with stable margins)
Bull: Manufacturing hedging robust and multi-legged (FCI fixed supply, maize futures, ENA flex-pricing)
Bull: Capital discipline—P&A and UP growth self-funded without major capex through FY29
Bull: UP market at 95 lakh cases/month; Globus at 0.2M/month implies 2–3 years of runway
Bear: ₹363 Cr (32%) of revenue unattributed; sub-1% implied margin raises transparency concerns
Bear: Consolidated NPM 2.3% vs 4% on core business. Quality-of-earnings red flag.
Bear: Glass/PET inflation 10–17% YoY with no quantified cost-pass strategy; margin absorption unproven
Bear: P&A EBITDA −₹13 Cr with no breakeven timeline disclosed. Strategy credible, execution runway vague.
Bear: Stock down 5.55% by day 5 post-result and 29.72% from ATH. Market has not bought the narrative.
Risks, ranked by holder concern
Margin compression from glass/PET inflation
HighGlass costs up 10–17%; PET in double digits. Consolidated NPM already 2.3% with little absorption headroom. No detailed cost-pass mechanism disclosed.
Revenue disclosure gap and data quality
High₹363 Cr (32%) unattributed. Raises segment accounting questions. Suggests possible sandbagging of near-term guidance or undisclosed low-margin channels.
P&A profitability timeline vague
MediumEBITDA −₹13 Cr acceptable 'for now'. No breakeven timeline disclosed. If path extends beyond 2–3 years, capex/investment thesis weakens.
UP R&O growth normalization
Medium2.4x from low base is impressive. But mgmt refused to quantify forward growth ('very difficult'). Risk: growth normalizes if competition or market saturation hits.
FX headwind vs tariff upside
LowUK FTA tariff cuts expected, but Rupee 20% depreciation vs Pound YoY offsets. Mgmt said net impact 'not very significant'. Upside optionality only.
How the street is positioned
The market's own verdict: The stock fell 1.62% on day 1, widened to 5.72% loss by day 3, and held at −5.55% by day 5 post-announcement. The sell-off did not fade—it solidified. This signals: volume growth is table stakes; the market's concern is margin compression, undisclosed revenue quality, and P&A profitability uncertainty.
₹880.45
as of 24 Jul 2026
₹1,252.80
−29.72% from peak
₹800.05–₹1,252.80
+10.05% off lows
42.5
neutral; oversold risk below 30
₹913.95 / ₹888.65 / ₹972.24
stock below all key averages
The stock sits 29.72% below its all-time high and trades below its 20-, 50-, and 200-day moving averages. RSI 42.5 suggests neutral-to-oversold territory with further downside risk. Notably, this drawdown predates the Q1 result—the post-result sell-off merely confirmed pre-existing hesitation.
Ownership flows: FII increased 1.06 percentage points QoQ to 7.53%, and DII added 0.82pp to 10.93%. Institutional buying exists but insufficient to counter the stock's decline. Promoter ownership inched down 0.17pp to 50.58%, stable but not a vote of confidence. Absence of reported insider buying or block trades near highs suggests insiders are equally cautious.
1 · Q2 margin trajectory—glass/PET inflation pass-through
Will Globus successfully pass glass costs (10–17% inflation) to consumers, or will margins compress further? Consolidated NPM of 2.3% leaves little absorption room.
2 · UP R&O quarterly growth rate—does 2.4x sustain or moderate?
Mgmt refused Q2+ quantification. Watch UP volumes and revenue in Q2 for evidence of whether the 2.4x rate holds or normalizes. This is the bull thesis engine.
3 · West Bengal R&O clearance and re-entry timeline
Mgmt said final approval expected this quarter, re-entry within 60 days of clearance. Material upside catalyst if realized; any delay is a red flag.
4 · P&A path to profitability—quantified timeline
Watch for when P&A is expected to turn profitable. Negative EBITDA (−₹13 Cr) acceptable only if breakeven is 2–3 years away, not a prolonged slog.
Globus delivered volume growth across all segments and reaffirmed manufacturing margin guidance. But the quarter is a mixed read: strong execution masked by undisclosed low-margin business (₹363 Cr gap), margin compression (NPM 2.3%), and P&A losses without a clear profitability timeline. The stock's 29.72% decline from all-time high and post-result sell-off reflect the market's verdict—this is not a game-changer.
For holders, focus shifts to Q2. Track consolidated net profit margin: if it stays above 2% and UP R&O sustains double-digit growth, the bull thesis holds. If margins compress further with no cost-pass evidence, or if UP growth normalizes sharply, re-evaluate on weakness.
For new entrants, wait for clarity on P&A profitability and consolidated margin stabilization. The risk-reward is balanced, not compelling—steady execution, not a step-change. The number to track from here is consolidated NPM: anything below 2% signals a downgrade.
Globus Spirits Q1: consolidated PAT up 50% YoY to ₹26.5 Cr on manufacturing margin rebound
PAT +49.69% YoY · revenue +21.05% · margins expanding
₹1,151.88 Cr
+21.05% YoY
₹26.48 Cr
+49.69% YoY
2.3%
+0.4pp YoY
₹9.14
Globus Spirits opened FY27 with a strong quarter on a consolidated basis: net profit rose ~49.7% YoY to ₹26.5 Cr (₹17.7 Cr a year ago) and EPS climbed to ₹9.14 from ₹6.16. Reported revenue from operations of ₹1,151.9 Cr was up 21.1% YoY, but that headline is flattered by excise duty (₹363 Cr, +44% YoY, a pass-through) — the cleaner net-of-excise topline grew ~12.7% YoY to ₹788.8 Cr. Standalone told the same story slightly stronger: PAT ₹27.6 Cr (+48.7% YoY), the consolidated number sitting below it purely because of a ₹0.84 Cr share of joint-venture (Globus ANSA) loss and a small loss at subsidiary Bored Beverages — no divergence in the underlying trend.
Q1 FY-2027 vs prior quarters
The profit engine was margin, not just volume. Net profit margin widened to 2.30% from 1.85% a year ago, driven almost entirely by the Manufacturing segment, whose EBITDA jumped ~66% YoY to ₹36.9 Cr as spirit economics recovered; Consumer EBITDA grew a steadier ~13% YoY to ₹42.4 Cr. The 35% QoQ revenue and 25% QoQ PAT jump over Q4 FY26 is largely seasonality (Q1 is the seasonally stronger period for the spirits/agri cycle) and should be read as supporting, not headline, detail.
The stock went into the print at ₹992.4, up 14% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters; revenue is at a 6-quarter high.
Management reaffirms its FY29 vision, notably targeting INR 500 crores in P&A revenue, driven by scaling emerging markets. For FY27, the manufacturing segment's EBITDA is guided to remain stable at INR 5-7 per liter, with volumes expected to grow with the new UP facility. The Regulars & Others consumer segment is poise
— This quarter: met
Against management's own prior guidance the print is broadly on-track: Consumer revenue rose ~15.6% YoY, comfortably ahead of the >7% growth ambition management set on the FY26 call, and the Manufacturing EBITDA-per-litre stability thesis is visible in the segment's sharp margin recovery. The one gap is Consumer segment margin at ~13.4%, still short of the 16-17% normalization management targeted — the volume inflection is here, the margin normalization is not yet. There is no formal quarterly guidance or street consensus on record for this mid-cap; the analyst concall is scheduled for July 20, 2026. Alongside the results the Board (meeting July 17) also noted allotment of 12,373 ESOP shares, lifting the share count to 2.908 Cr. The unresolved income-tax matter (search/seizure; ₹40.94 Cr aggregate demand, ₹30.44 Cr already paid under protest) carries no P&L provision as management expects to prevail on appeal — a contingent overhang to track, not a current charge.
What to watch
W1
Consumer segment EBITDA margin at ~13.4% vs management's stated 16-17% normalization target — next 1-2 quarters test whether margins catch up to the volume inflection
W2
Manufacturing EBITDA/litre holding in the guided ₹5-7 range plus volume ramp from the new UP facility
W3
Income-tax appeal outcome — ₹40.94 Cr demand, ₹30.44 Cr already paid under protest, currently unprovided